miR‐210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells by Angel, Charlotte Zoe et al.
Title: miR-210 is Induced by Hypoxia and Regulates Neural Cell Adhesion Molecule in Prostate Cells 
Running Title: Role of hypoxia-induced miR-210 in prostate cancer 
Authors : Charlotte Zoe Angel1, Seodhna M. Lynch2, Heather Nesbitt1, Michael M. McKenna3, Colum 
P. Walsh1, Declan J. McKenna1*  
Affiliations:   







2 School of Biomolecular and Biomedical Science,  
Conway Institute  




3 Department of Cellular Pathology  
Western Health & Social Care Trust 
Altnagelvin Area Hospital  




* Corresponding author: 
Dr Declan McKenna 
Biomedical Sciences Research Institute 









Funding for this research was provided by a PhD Studentship Award from the Department for the 
Economy (DfE), Northern Ireland.  
 
CONFLICT OF INTEREST STATEMENT 
The authors declare no competing interests.  
ABSTRACT 
Hypoxia in prostate tumours has been associated with disease progression and metastasis. MicroRNAs 
are short non-coding RNA molecules which are important in several cell processes, but their role in 
hypoxic signalling is still poorly understood. miR-210 has been linked with hypoxic mechanisms, but 
this relationship has been poorly characterised in prostate cancer. In this report the link between 
hypoxia and miR-210 in prostate cancer cells is investigated. 
PCR analysis demonstrates that miR-210 is induced by hypoxia in prostate cancer cells using in vitro 
cell models and an in vivo prostate tumour xenograft model. Analysis of The Cancer Genome Atlas 
(TCGA) prostate biopsy datasets shows that miR-210 is significantly correlated with Gleason grade and 
other clinical markers of prostate cancer progression. NCAM is identified as a target of miR-210, 
providing a biological mechanism whereby hypoxia-induced miR-210 expression can contribute to 
prostate cancer. 
This study provides evidence that miR-210 is an important regulator of cell response to hypoxic stress 









It is well established that hypoxia, defined as a level of oxygen tension below the normal physiologic 
level, occurs in most solid tumours (McKeown, 2014; Muz et al, 2015). Hypoxia develops in tumours 
due to the deregulated proliferation of cancer cells away from their blood supply and the increasingly 
chaotic and leaky structure of tumour vasculature (Fraga et al, 2015). This is an important factor in 
cancer progression because hypoxic stress triggers a complex network of cellular and molecular 
responses that can promote tumour growth (Muz et al, 2015; Araos et al, 2018). This is particularly 
significant for prostate tumours which are known to be very hypoxic in comparison to normal prostate 
tissue (McKeown et al, 2014; McKenna et al, 2018). Prostate tumour hypoxia has been implicated as a 
contributory factor in malignant progression (Rudolsson et al, 2009; Tsai & Wu, 2012), genetic instability 
(Taiakina et al, 2014), epithelial-to-mesenchymal transition (EMT)(Byrne et al, 2016; Li et al, 2016) and 
the selection of cells with diminished apoptotic potential and a greater invasive potential (Butterworth 
et al, 2008; Graeber et al, 1996). However, although many of the biological pathways involved in the 
hypoxic response have been investigated (Muz et al, 2015), the role of microRNAs (miRNAs) is only 
beginning to emerge and be understood.  
miRNAs are short, non-coding RNAs that direct the degradation or translational inhibition of messenger 
RNAs (mRNAs). miRNAs are known to regulate many essential cell processes including the cell cycle, 
apoptosis, metabolism, differentiation, and immunosuppression, as well as facilitating local and 
systemic interactions by being transmitted in vesicles such as exosomes and in bodily fluids (Hayes et 
al, 2014). It is therefore unsurprising that the abnormal expression of individual miRNAs is associated 
with many diseases, including cancer (Iorio & Croce, 2012). In prostate cancer, several miRNAs are 
expressed aberrantly, but the precise ways in which they contribute to the development and progression 
of cancer remains to be fully explained (Sharma & Baruah, 2019; Kanwal et al, 2017). Moreover, few 
microRNAs have been specifically investigated in relation to hypoxia in prostate cancer. 
One miRNA that has been consistently linked with hypoxia in various tissues is hsa-miR-210-3p (miR-
210), to the extent that it is now considered a major regulator of the hypoxic response (Bavelloni et al, 
2017). Many studies have shown how miR-210 contributes to several important cell processes, 
including angiogenesis (Lin et al, 2018), DNA damage response (Crosby et al, 2009), cell proliferation 
and apoptosis (Zhang et al, 2015), through regulation of key gene targets. Hence, abnormal expression 
of miR-210 can impact dramatically on cell behaviour, with a large body of evidence now gathered 
which links it with cancer development (Bavelloni et al, 2017; Dang & Myers, 2015). For example, 
overexpression of miR-210 has been associated with breast (Li et al, 2013; Madhavan et al, 2012; 
Camps et al, 2008), renal (Petrozza et al, 2017), lung (He et al, 2018), colorectal (Sabry et al, 2018) 
and pancreatic (Greither et al, 2010) cancers among others. Together, these studies indicate a vital 
contributory role for miR-210 in cancer development, as well as demonstrating its potential value as a 
prognostic cancer marker (Liu et al, 2017). Given its well-established role as a hypoxic regulator, it 
seems reasonable to presume that the miR-210 over-expression is a reflection of the hypoxia that 
occurs in most tumours. 
However, even though prostate tumours are known to be very hypoxic, it appears that only a few studies 
have investigated a role for miR-210 in prostate cancer. Of those that have, recent studies have found 
that over-expression of miR-210 in primary prostate tumours has been shown to correlate with 
lymphogenic metastatic (Eminaga et al, 2018) and bone metastatic (Dai et al, 2017; Ren et al, 2017) 
disease. Likewise, sera from patients with prostate cancer have higher levels of miR-210 (Qu & Huang, 
2018; Cheng et al, 2013). In vitro work has shown that miR-210 targets key players in the NF-κB (Ren 
et al, 2017)  and TGF-(Dai et al, 2017) signaling pathways, while others have suggested miR-210 
expression in stromal fibroblasts can contribute to prostate tumour progression (Taddei et al, 2014; 
Andersen et al, 2016) through promotion of EMT (Taddei et al, 2014). However, none of these studies 
have specifically examined the link between hypoxia and miR-210 in prostate cancer. Thus, there is still 
a clear need to study miR-210 to improve understanding about how hypoxia can drive prostate cancer. 
Therefore, in this study, we investigated the expression and regulatory mechanisms of miR-210 in 






Cell culture and transfections. All cell-lines were obtained from American Type Culture Collection 
(ATCC, Rockville, MD, USA). Cells were frozen at low passage number and used within 3-6 passages 
after thawing. Cells were authenticated by in-house genotyping service and routinely tested as 
mycoplasma-free (InvivoGen, Toulouse, France). Non-malignant prostate epithelial cell-line RWPE1 
was cultured in keratinocyte growth medium supplemented with 5ng/ml human recombinant epidermal 
growth factor and 0.05mg/ml bovine pituitary extract (Life Technologies, Paisley, UK). Human prostate 
cancer cell-lines LNCaP, 22RV1 and PC3 were cultured in RPMI-1640 supplemented with 10% FBS 
and L-glutamine (Life Technologies). All cells were grown in an incubator with a humidified atmosphere 
of 95% air and 5% CO2 at 37°C and routinely passaged. For treatment in hypoxic conditions, cells were 
placed in normoxia (20% oxygen) or hypoxia (0.1% oxygen) at 37°C in a hypoxia work station (Ruskinn 
Technology, UK) for up to 72 hours. For spheroid cell culture, 6-well plates were double-coated with a 
polyhema acrylamide layer (1.2% poly(2-hydroxyethyl methacrylate) in 95% ethanol) to prevent cell 
adhesion to the base of the plate. 30,000 LNCaP cells were seeded per well, media was replaced every 
2-3 days and average spheroid size (n=20) was measured by microscopy. For miRNA transfections, 
RWPE1 cells were seeded at 80,000 cells/well in a 6-well plate. After 24 hrs, cells were transfected with 
miR-210 (pre-miR-210) or non-targeting negative control (pre-miR-neg) (both Life Technologies) at a 
final concentration of 25nM using Lipofectamine 2000 (Life Technologies). After 72 hours, cells were 
harvested for RNA or protein extraction.  
Luciferase Reporter Assay. Luciferase reporter plasmid constructs were a kind gift from Dr Fabio 
Martelli as previously published (Fasanaro et al, 2009). One construct contained the wild-type NCAM1 
3’UTR region with the miR-210 binding site intact (WT-3’UTR). A matched control construct (DEL-
3’UTR) contained deletions in the seed region of the miR-210 binding site. Cells were seeded at a 
concentration of 20,000 cells/well in 24 well plates and transfected with 300ng of either WT-3’UTR 
plasmid or DEL-3’UTR, together with either pre-miR-210 or control pre-miR-neg oligonucleotides at a 
concentration of 25nM. 30ng Renilla luciferase vector was included in each well to control for 
transfection efficiency. After 48 hours, cells were lysed in lysis buffer (Promega, Southampton, UK) and 
luciferase activity measured using the Dual-Glo® Luciferase Assay Kit (Promega) on a FluoStar Omega 
plate reader (BMG LabTech, Aylesbury, UK). Transfections were carried out in triplicate, measurements 
within experiments were performed in duplicate, and firefly luciferase readings were normalised against 
renilla luciferase readings before analysis.    
RNA Extraction from FFPE Human Prostate Tumour Samples. 
Formalin Fixed Paraffin Embedded (FFPE) prostate cancer samples were obtained from Altnagelvin 
Area Hospital, Derry. Use of patient material and information, as well as research protocols, were 
approved by ORECNNI (Ref. 10/NIR0213), which included informed consent from patients. For 
preparation of RNA from FFPE prostatectomy biopsy samples (n = 17), five 10µM sections containing 
>50% tumour were cut for RNA extraction. Sections of matched normal prostate tissue from the 
unaffected lobe of the same patient were similarly cut. RNA extraction on all FFPE tissue was performed 
using the RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (Life Technologies) following 
manufacturer’s instructions.  
PCR Analysis 
RNA extraction was carried out using Tripure® (Life Technologies) according to manufacturer’s 
instructions. 1µg RNA was used for first strand cDNA synthesis using random primers with transcriptor 
high-fidelity cDNA synthesis kit (Roche, Sussex, UK) according to manufacturer’s instructions.  For 
quantitative Real-time PCR (qRT-PCR), amplification of PCR products was quantified using FastStart 
SYBR Green Master (Roche) on a Roche LC480 Lightcycler, using primer sets for NCAM1 (fw: 
TGCGACCATCCACCTCAAAG, rv: CCAGAGTCTTTTCTTCGCTGC), PTEN (fw: 
ACCCACCACAGCTAGAACTT, rv: GGGAATAGTTACTCCCTTTTTGTC), POU5F1 (fw: 
TGGGGGTTCTATTTGGGAAGG, rv: GATCTGCTGCAGTGTGGGT),  HPRT  (fw: 
CCTGGCGTCGTGATTAGTGA, rv: CGAGCAAGACGTTCAGTCCT). Expression was normalised to 
HPRT and graphs represent the combined results of three independent biological replicates.  
qRT-PCR of miRNAs was performed using the miRCURY LNATM microRNA PCR system (Exiqon, 
Vedbaek, Denmark). 50ng (clinical samples) or 20ng (cell-line samples) template RNA was used in 
each first strand cDNA synthesis reaction. PCR was performed over 40 amplification cycles and 
fluorescence monitored on the Roche LC480 Lightcycler. For all qRT-PCR miRNA analysis, 
normalisation was against U6snRNA or SNORD48 and graphs represent the combined results from 3 
independent biological replicates, unless otherwise indicated.  Serum miRNA was extracted using a 
column-based RNA isolation kit (Exiqon) using 5μL serum. miR-191 was used as housekeeping control 
for PCR analysis of serum miRNA expression. 
Protein analysis 
Protein was extracted from spheroids using urea buffer.  Primary antibodies used for blotting were anti-
HIF-1 (Sigma, Dorset, UK), anti-NCAM (Santa Cruz Biotechnology, Heidelberg, Germany) with anti-
α-Actin (Sigma) as loading control. Membranes were blocked in 5% milk diluted in 1x TBS-T (0.05%) 
followed by incubation in the appropriate secondary antibody (goat anti-rabbit IgG-HRP (1:10000) or 
goat anti-mouse IgG-HRP (1:10000))(both Santa Cruz). Luminescence was revealed by incubation with 
enhanced chemiluminescent reagent (Life Technologies) and signal detected on a G:BOX F3 imaging 
system (Syngene, Cambridge, UK). 
 
In vivo methods 
Animal maintenance and care. In vivo experiments were conducted in accordance with the Animal 
(Scientific Procedures) Act 1986 and the UKCCCR guidelines for the welfare of animals in experimental 
neoplasia (Workman et al, 1988). 8-10 week old male nude mice weighing 25-30g (Envigo, 
Cambridgeshire, UK) were housed under standard laboratory conditions in a temperature controlled 
(22ºC; 50-55% humidity) specific pathogen-free environment with a 12-hour light/dark cycle. Food and 
water were supplied ad libitum. Procedures and administrations were performed using aseptic 
technique, and tumour implantation and oxygen electrode measurement were performed under 
anaesthesia. The work was approved by the ethical review committee of Ulster University and covered 
by establishment licence and project licence.  
Xenograft establishment. LNCaP xenografts were established on nude mice by subcutaneous 
injection of 5x106 cells suspended in 100μl of ice-cold matrigel (Corning, growth factor reduced) to the 
dorsum, using a cold 21g needle. Once the tumour became palpable, dimensions were measured using 
Vernier calipers, using the formula: volume = (height x height x width)/2.  
Oxygen electrode measurement. A fibre optic probe (OxyLite®) was inserted into the tumour 
(avoiding proximity to blood vessels) through a 21g needle. After the probe readings had normalised, 
30 readings were recorded per site (the median reading was used). At least two sites (with similar 
readings) were measured per tumour and the mean of the 2 median readings was taken to represent 
the tumour. 
Drug administration. Bicalutamide (Sigma) was prepared in vehicle (0.1% DMSO in corn oil) and 
administered orally via gavage at 6mg/kg daily. When tumour volume reached between 150mm3, mice 
were randomly assigned to treatment groups and dosing was initiated.  
Databases and online tools utilised 
To identify mRNA targets of the miRNAs, the databases miRTarBase (Chou et al, 2018) 
(http://mirtarbase.mbc.nctu.edu.tw) and miRWalk2.0 (Dweep & Gretz, 2015) (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/index.html) were searched to find consistently predicted targets. 
Some results published here are in part based upon data generated by The Cancer Genome Atlas 
(TCGA) Research Network: (http://cancergenome.nih.gov/). TCGA analysis was performed using 
Regulome Explorer (http://explorer.cancerregulome.org/) and Firebrowse (http://firebrowse.org/) 
analysis tools. Regulome Explorer analysis was based on a single primary prostate cancer dataset  
(TCGA Research Network, 2015). Firebrowse analysis was based on larger cohort of prostate 
adenocarcinoma (PRAD) samples (Broad Institute TCGA Centre (2016). Survival analysis was 
performed using both KM Express (Chen et al, 2018) (http://ec2-52-201-246-161.compute-
1.amazonaws.com/kmexpress/index.php) and Human Protein Atlas (Uhlen et al, 2015) 
(https://www.proteinatlas.org/) analysis tools. KEGG and Gene Ontology analysis was performed using 
DAVID Bioinformatics Resources 6.8 (Huang et al, 2009a; 2009b)(https://david.ncifcrf.gov/). 
Statistical analysis 
Unless otherwise indicated, all data were analysed using a two-tailed student’s t-test, with Welch’s 
correction where appropriate, using the Prism 5.0 software (GraphPad). Regulome analysis of TCGA 
dataset was based on All Pairs Statistical Associations and utilised Spearman’s rank correlation, with 
p-values adjusted for multiple hypothesis testing. For Firebrowse analysis, Spearman's rank correlation 
and two-tailed P values were estimated using 'cor.test' function in R. For multiple hypothesis testing, p-
values were converted to Q-value using the Benjamini and Hochberg correction. KM Express survival 
analysis was performed using R package ‘survival (Therneau, 2015). Differences between points were 
deemed statistically significant with a p<0.05 (95% confidence interval). 
  
RESULTS 
Hypoxia upregulates miR-210 in prostate cancer cells. 
Growing LNCaP prostate cancer cells in hypoxic (0.1% O2) conditions resulted in in significant miR-210 
upregulation compared to 20% O2 (Figure 1A). The induction of hypoxia in these cells was confirmed 
by upregulation of hypoxic marker genes PTEN and POU5F1 (Figure 1B) and HIF-1 protein (Figure 
1C). The induction of miR-210 in response to hypoxia was also noted in 22RV1 and PC3 prostate 
cancer cells, as well as normal RWPE1 epithelial prostate cells, following growth in 0.1% O2 
(Supplementary Figure 1). In LNCaP spheroid models, miR-210 expression was also increased when 
spheroids became hypoxic after ~14 days growth (Figures 1D – 1F). Induction of hypoxia was 
evidenced by induction of HIF-1 protein in spheroids which had reached ~50M in size (Figure 1G).  
We also employed a murine LNCaP xenograft model which we have previously used to study tumour 
hypoxia in response to bicalutamide treatment (Byrne et al, 2016; Nesbitt et al, 2017). As expected, 
tumour growth was significantly inhibited by bicalutamide treatment after 28 days, in comparison to 
vehicle treated tumours (Figure 2A). As we previously shown in similar models, bicalutamide treatment 
induces profound tumour hypoxia after 7 days (Figure 2B), resulting in HIF-1 stabilization (Figure 2E). 
An induction of miR-210 is shown which becomes significant after 28 days (Figure 2C), when tumour 
hypoxia is still apparent. There was also an induction of miR-210 in serum at Day 7, although this fell 
short of significance (Figure 2D).  
miR-210 is associated with markers of prostate cancer progression. 
We successfully measured miR-210 levels in in 17 matched pairs of normal and tumour tissue from 
clinical FFPE prostate biopsies (Figure 3A). Up-regulation as well as down-regulation of miR-210 was 
observed in tumour tissue compared to paired normal tissue, which we suggest is indicative of the 
relative hypoxic status of cells within an individual tumour, which in turn may provide useful diagnostic 
or prognostic information. We also noted with interest that there was a trend for higher miR-210 
expression as Gleason score increased in these samples, even allowing for the small number of 
samples (Figure 3B). When we progressed to perform similar analysis on much larger numbers of 
samples, using TCGA datasets, we showed that increased miR-210 expression was indeed significantly 
increased in tumours with higher Gleason, as well showing significant positive correlation with tumour 
stage and lymph node metastasis (Figures 3C and 3D). When cases were split into high and low miR-
210 expression, it was evident that high miR-210 expression resulted in significantly shorter time of 
disease-free progression (Figure 3E). To further evidence that the increased expression of miR-210 is 
associated with hypoxia in clinical samples, we examined expression of various hypoxia-related genes 
in a well-characterized TCGA dataset (n=330). This showed that EZH2, another marker of prostate 
tumour hypoxia (zhou et al, 2018), has a strong positive correlation with miR-210 expression in these 
samples (Figure 3F). Likewise, the hypoxia-induced genes SPP1 and DLGAP5, which code for 
ostepontin and HURP proteins respectively, also show significant positive correlation with clinic-
pathological parameters of prostate cancer progression (Supplementary Figure 2). Finally, KEGG 
analysis and Gene Ontology mapping of validated miR-210 targets demonstrates that miR-210 is 
significantly associated with both prostate cancer and hypoxia-related cell processes (Supplementary 
Tables 1 and 2). This in silico analysis corroborates our laboratory results in demonstrating that miR-
210 is likely to be a key mediator of the hypoxic response in prostate cancer. 
Neural cell adhesion molecule (NCAM) is a direct target of miR-210.  
Using bioinformatics prediction tools, we had identified the gene NCAM1 as a potential target of miR-
210 (Figure 4A), so we proceeded to investigate how its expression correlated with miR-210 in prostate 
cancer. To test this relationship in vitro, we tested prostate cell-lines to identify one that expressed 
detectable levels of NCAM protein (Figure 4B), and subsequently selected RWPE1 cells in which to 
over-express miR-210 by transient transfection (Figure 4C). NCAM1 levels as measured by qPCR were 
decreased, although this was not significant, probably because the mRNA is incompletely degraded by 
the binding and can still be amplified, albeit to a reduced extent (Figure 4D). However, at the protein 
level there was a marked reduction in NCAM levels, suggesting miR-210 can indeed regulate levels of 
functional NCAM (Figure 4E). We confirmed that NCAM1 was a direct target of miR-210 with a 
luciferase reporter assay (Figure 4F). The luciferase activity of a reporter construct containing the wild-
type NCAM1 3’UTR region (WT-3’UTR) showed significant reduction when miR-210 was over-
expressed in the same cells. However, when miR-210 was over-expressed with a reporter construct 
which had deleted residues in the miR-210 binding site of NCAM1 3’UTR (DEL-3’UTR), no reduction in 
luciferase activity was observed, therefore indicating that NCAM1 is a direct target of miR-210 in these 
cells. Hence, through this mechanism, the hypoxia-induced expression of miR-210 has the potential to 
impact upon cell adhesion processes.  
miR-210 and NCAM expression is inversely correlated in prostate tissue 
We hypothesised that increased hypoxia in prostate epithelial cells and tumours induces miR-210 which 
in turn decreases the levels of NCAM1, so we explored TCGA datasets to investigate this relationship. 
We found that a significant inverse correlation does indeed exist between miR-210 and NCAM1 gene 
expression in prostate biopsy tissue (Figure 5A). Expression of NCAM1 also showed a significant 
negative correlation with clinicopathological markers of prostate cancer progression (Figure 5B), in 
contrast to the positive correlation observed for miR-210 (Figure 3C). As an illustrative example, 
NCAM1 expression is higher in tumours with Gleason Score ≤ 7, compared to those with Gleason score 
≥ 8 (Figure 5C), whereas the opposite is true for miR-210 (Figure 3D). Survival analysis indicates that 
NCAM1 expression is associated with lower survival probability at >10 years, but this association falls 
short of significance, so NCAM1 expression by itself it would not be considered a reliable prognostic 




Prostate tumours are recognised as being very hypoxic, so it is surprising that few studies have 
specifically investigated how this impacts upon miR-210, a microRNA which has been consistently 
linked with the hypoxic response. Hence, this is the first report to present research showing how the 
relationship between tumour hypoxia and miR-210 can contribute to prostate cancer development 
through its regulation of NCAM levels.  
We have provided evidence that miR-210 is induced by hypoxia in in vitro and in vivo models of prostate 
cancer. In our previous in vivo work we demonstrated how hypoxia can be induced in a xenograft tumour 
model by bicalutamide, a phenomenon which we proposed may drive the metastatic and invasive 
potential of prostate tumour cells (Byrne et al, 2016; Nesbitt et al, 2017). Here, we show that the hypoxic 
stress up-regulates miR-210, which will in turn influence a number of genes and cell processes linked 
to tumour growth. The analysis of clinical biopsy samples presented here also supports the link between 
the hypoxic nature of prostate tumours, increased expression of miR-210 and prostate cancer 
progression. It is also interesting to note that increased miR-210 expression decreases time of disease-
free survival. This substantiates our previous findings which suggested increased tumour hypoxia was 
a key contributory factor in prostate cancer relapse. Taken together, it therefore seems clear that the 
hypoxia which is well-known to exist in prostate tumours does result in over-expression of miR-210, 
which in turn can cause cellular dysfunction through its impact upon many biological pathways. 
To explore potential novel mechanisms of miR-210 action, we progressed to analyse its effect on the 
translation of neural cell adhesion molecule (NCAM), a large cell surface receptor from the 
immunoglobin superfamily. NCAM, also known as CD56, is classically known as a cell surface molecule 
which plays an important role in neurons (Aonurm-Helm et al, 2016), haematopoietic stem cells 
(Simmons et al, 2001) and immune cells (Van Acker et al, 2017). It is encoded  by the gene NCAM1 
and three splice variants exist, giving rise to proteins of approximately 180 kDa, 140 kDa or 120 kDa in 
weight (Aonurm-Helm et al, 2016). These facilitate interactions with other cells through both homophillic 
NCAM binding and heterophillic binding with other molecules, such as fibroblast growth factor receptor 
(FGFR) on the surface of T cells (Kos & Chin, 2002). However NCAM is also involved in many other 
roles in other cell types including exon guidance and repair, migration, apoptosis and cell proliferation 
(Jensen & Berthold, 2007). In cancer, its role appears to be context-dependent. Neoplasms of 
neuroendocrine or hematopoietic origins over-produce NCAM, as do brain tumours (Jensen & Berthold, 
2007; Zecchini & Cavallaro, 2010). Conversely, in pancreatic (Fogar et al, 1997), colorectal (Roesler et 
al, 1997) astrocytic (Sasaki et al, 1998) and thyroid (Muthusamy et al, 2018; Pyo et al, 2018)  cancer, 
low levels of NCAM have been correlated with increased malignancy. In prostate cancer, however, the 
role of NCAM has not been investigated.  
In this study we have demonstrated that miR-210 targets NCAM1 in prostate cells. Only one previous 
study had identified NCAM1 as a target of miR-210 (Fasanaro et al, 2009), but ours is the first study to 
demonstrate this interaction may be important in a cancer setting. Interestingly, we found that none of 
the NCAM protein isoforms were detectable in cancer cell-lines, so we conducted these experiments in 
RWPE1 cells where the 120kDa variant was found at detectable levels. The absence of NCAM protein 
expression in prostate cancer cell lines suggests that its loss might be important in the carcinogenesis 
of prostatic epithelial cells. Indeed, our analysis of TCGA data demonstrates that low expression of 
NCAM1 is associated with markers of aggressiveness. Our survival analysis in prostate cancer did not 
show a significant correlation for NCAM1, but it is worth noting that low expression of NCAM1 is 
significantly associated with lower 5-year survival probability in pancreatic cancer (Supplementary Fig 
3B). Given these findings, we propose that induction of miR-210 can leads to loss of NCAM which could 
potentially promote tumour growth in two ways. First, it would allow cells to evade immune response by 
decreasing the cell-cell interaction with CD56+ NK cells, FGFR+ T cells, or macrophages. Second, the 
loss of NCAM binding between with neighbouring cells and the extracellular matrix (ECM) could allow 
prostate cells to detach from their location and spread. In addition, miR-210 will also impact upon cell 
behaviour through the rest of its regulatory network (Supplementary Figure 4).  
In summary, this is the first study to show that hypoxia-induced expression of miR-210 in prostate cells 
regulates NCAM expression. We have shown that miR-210 is significantly upregulated by hypoxia in 
prostate cells in vitro and in vivo, as well as demonstrating that miR-210 expression is positively 
correlated with tumour aggressiveness in human prostate cancer tissue. This study provides evidence 
for the use of miR-210 as a diagnostic or prognostic marker in prostate cancer, and may also be a 
potential target for therapeutic intervention. 
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Figure 1. Expression of miR-210 in hypoxic prostate cancer cells in vitro 
(A) qRT-PCR analysis showed increased expression of miR-210 and (B) POU5F1 and PTEN in LNCaP 
cells exposed to hypoxia (C) Western blot analysis shows increased expression of HIF-1 in LNCaP 
cells exposed to hypoxia. (D & E) LNCaP spheroid growth over 15 days is associated with increase in 
(F) miR-210 expression and (G) HIF-1 expression. PCR data was normalised to either HPRT or 
U6snRNA and data shown is mean ± SE of triplicate experiments. (Student t-test p-values: *p<0.05, 
**p<0.01, ***p<0.001).  
Figure 2. Expression of miR-210 in hypoxic prostate cancer xenograft model. 
(A) Graph shows tumour growth in LNCaP-luc xenograft Nude mouse following treatment with vehicle 
(0.1% DMSO in corn oil) and bicalutamide (6mg/kg/day)(n≥4 per group). (B) Oxygen levels in tumours 
from bicalutamide- and vehicle-treated mice (n≥4 per group) at 0, 7, 14, 28 days treatment. (2way 
ANOVA with Bonferroni post-test p-values: *p<0.05). (C) qRT-PCR analysis of miR-210 expression in 
(C) excised tumours at Day 7 and Day 28 and (D) serum at Day 7. Data is mean ± SE from triplicate 
experiments. (Student t-test values: *p<0.05). (E) Western blot analysis showing increased HIF-1 
expression in bicalutamide-treated tumours compared to vehicle at Day 7.  
Figure 3. Expression of miR-210 in clinical prostate biopsies. 
(A) qRT-PCR analysis of RNA isolated from FFPE biopsy clinical specimens (n=17) showing fold 
change expression of miR-210 in individual tumour cases relative to matched normal tissue (B) 
Expression of miR-210 in biopsies with different Gleason scores. (C) Firebrowse analysis of TCGA 
biopsy samples showing positive correlation of miR-210 with clinicopathological parameters (D) 
Regulome analysis of one TCGA dataset (n=330) shows miR-210 expression is increased in biopsies 
with Gleason score ≥8. (E) KM Express survival analysis of TCGA prostate data shows significantly 
shorter recurrence-free survival in patients with high miR-210 expression. (F) Regulome analysis shows 
miR-210 is positively correlated with hypoxic marker EZH2 in TCGA dataset (n=330). TCGA analyses 
utilised Spearman’s rank correlation, with p-values adjusted for multiple hypothesis testing. A p-value 
of < 0.05 and Q-value < 0.3 was deemed significant.  
Figure 4. NCAM is a direct target of miR-210  
(A) miR-210 is computationally predicted to target NCAM1 at three positions. TargetScan predicted 
pairing of target region in 3’ UTR of NCAM1 (bottom) and miR-210 (top), with the 8mer ‘seed sequence’ 
highlighted. Letters in bold indicate the deleted region for reporter constructs. (B) Western blot analysis 
of NCAM protein expression in normal epithelial prostate cell lines RWPE1 and four prostate cancer 
cell lines. (C) Following over-expression of miR-210 in RWPE1 cells (D) qRT-PCR and (E) western 
blotting shows that NCAM levels are decreased. (F) Luciferase activity reporter confirms miR-210 
targeting of NCAM1 in RWPE1 cells. A reporter construct containing the wild-type NCAM1 3’UTR region 
(WT-3’UTR) shows significant reduction of luciferase activity when co-transfected with precursor miR-
210 (pre-miR-210) relative to cells co-transfected with non-targeting control (pre-miR-neg). In cells 
transfected with a construct containing deleted residues in the miR-210 binding site of NCAM1 3’UTR 
(DEL-3’UTR), no reduction in luciferase activity is observed. Data in graphs is mean ± SE from triplicate 
experiments (Student t-test p-values: *p<0.05, **p<0.01, ***p<0.001).  
Figure 5.  miR-210 and NCAM1 are inversely correlated in TCGA clinical prostate samples 
(A) Regulome analysis shows miR-210 and NCAM1 are inversely correlated in TCGA clinical prostate 
dataset. (B) Firebrowse analysis of TCGA prostate biopsy samples showing negative correlation of 
NCAM1 with clinicopathological parameters. Both analyses utilised Spearman’s rank correlation, with 
p-values adjusted for multiple hypothesis testing. A p-value of < 0.05 and Q-value < 0.3 was deemed 
significant. (C) Analysis of TCGA dataset shows NCAM1 expression is decreased in biopsies with 
Gleason score ≥8. Data is mean ± SE (Unpaired t test with Welch's correction, p-values: **p<0.01). 
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SUPPLEMENTARY TABLE 1. Functional KEGG analysis of miR-210-3p target genes  
 
Disease Term Gene Count P-value Benjamini 
CANCER 38 0.0026 0.046 
tobacco use disorder 33 0.023 0.91 
breast cancer 11 0.0057 0.83 
ovarian cancer 9 0.0069 0.76 
prostate cancer 9 0.039 0.91 
lung cancer 9 0.041 0.9 
bladder Cancer 9 0.047 0.88 
 
Data shows highly significant association of miR-210 with cancer-related disease terms, mediated 
through various target genes of miR-210. P-value generated by modified Fisher Exact test. Benjamini 
value represents corrected P-value for multiple hypothesis testing using the Benjamini-Hochberg 
method to minimise false discovery rate. 
 
SUPPLEMENTARY TABLE 2. Functional gene ontology analysis of miR-210-3p target genes  
 




cellular response to oxygen levels  8 0.000092 0.047 
cellular response to oxidative stress  9 0.00022 0.048 
cellular response to hypoxia  7 0.00035 0.049 
cellular response to decreased oxygen levels  7 0.00047 0.054 
response to oxidative stress  11 0.00049 0.05 
response to oxygen levels  9 0.0018 0.11 
response to hypoxia  8 0.0043 0.17 
response to decreased oxygen levels  8 0.0051 0.19 
regulation of oxidative stress-induced cell death  4 0.0063 0.21 
 
Data shows highly significant association of miR-210 with selected GO classifications related to 
hypoxia and oxidative stress, mediated through various target genes of miR-210. Benjamini value 
represents corrected P-value for multiple hypothesis testing using the Benjamini-Hochberg method to 




Supplementary Figure 1. miR-210 expression in hypoxic 22Rv1, PC3 and RWPE1 cells. 
qRT-PCR analysis showed increased expression of miR-210 in 22Rv1, PC3 and RWPE1 cells exposed 
to hypoxia. PCR data was normalised to either HPRT and data shown is mean ± SE of triplicate 
experiments. (Student t-test p-values: *p<0.05, **p<0.01, ***p<0.001). 
  
 
Supplementary Figure 2. Expression of SPP1 and DLGAP5 in clinical prostate biopsies. 
(A) Regulome analysis of one TCGA dataset (n = 330) shows SPP1 expression is significantly 
correlated with Gleason score. Firebrowse analysis of TCGA prostate biopsy samples showing positive 
correlation of SPP1 with clinic-pathological parameters of disease progression. (B) Regulome analysis 
of one TCGA dataset (n = 330) shows DLGAP5 expression is significantly correlated with Gleason 
score. Firebrowse analysis of TCGA prostate biopsy samples showing positive correlation of DLGAP5 
with clinic-pathological parameters of disease progression. TCGA analyses utilised Spearman’s rank 
correlation, with p-values adjusted for multiple hypothesis testing. A p-value of < 0.05 and Q-value < 
0.3 was deemed significant.  
 
Supplementary Figure 3. Survival analysis  
(A) KM Express survival analysis of NCAM1 expression shows it is not significantly associated with 
lower 5-year survival in prostate cancer. (B) However, Human Protein Atlas survival analysis shows 
lower NCAM1 expression is associated with significantly shorter 5-year survival probability in 
pancreatic cancer. (image credit: Human Protein Atlas. image/gene/data available from v18.1. 
www.proteinatlas.org . Data available at https://www.proteinatlas.org/ENSG00000149294-




Supplementary Figure 4. miR-210 Regulatory network  
Network analysis using the miRTarbase website (http://mirtarbase.mbc.nctu.edu.tw/index.php) 
reveals that miR-210 impacts upon several other targets. Likewise, NCAM1 is regulated by other 
miRNAs. Accession ID: MIRT003159 [miRNA, hsa-miR-210-3p :: NCAM1, target gene] 
 
 
 
  
 
  
 
  
 
  
 
